13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001608126
Total reported value
$2.8B
$2.8B
9 檔
62.1%
According to the latest 13F quarterly dataset, Finepoint Capital LP managed an equity portfolio of $2.8B at the end of Q3 2025, spanning 9 distinct U.S. exchange-listed positions.
In Q3 2025, Finepoint Capital LP adopted a defensive or profit-taking posture, trimming 1 positions and completely liquidating 18 holdings to manage risk exposure.
In terms of portfolio concentration, the top 5 core holdings (including SPY, QXO, IWM) accounted for 62.1% of total reported equity market value during Q3 2025.
Top New Position Initiated
RXO
市值: $111.8M
Top Position Liquidated / Trimmed
LBRDK
前期市值: $45.0M
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | SPY | Ss Spdr S&p 500 ETF Trust-us | ETF-Large Cap & Growth | 46.26% | +10.54% | +2.90% | |
| 2 | QXO | Qxo Inc | Stock-Industrials | 24.44% | -2.60% | +5.40% | |
| 3 | IWM | Ishares Russell 2000 ETF | ETF-Small Cap | 22.50% | — | +176.41% | |
| 4 | RXO | Rxo Inc | Stock-Other | 6.43% | -2.26% | — | |
| 5 | SLDB | Solid Biosciences Inc | Stock-Other | 0.34% | — | — | |
| 6 | ANNA | Aleanna Inc | Stock-Other | 0.01% | -0.01% | — | |
| 7 | ANNAW | Aleanna Inc - Cl A - 29 | Stock-Other | 0.01% | -0.01% | — | |
| 8 | ✓ | Moneyhero Limited | Stock-Other | 0.01% | — | — | |
| 9 | CLDI | Calidi Biotherapeutics Inc | Stock-Other | — | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | SPY | Ss Spdr S&p 500 ETF Trust-us | +14.1% | +2.90% | Add |
| 2 | SLDB | Solid Biosciences Inc | +0.1% | — | Unchanged |
| 3 | ✓ | Moneyhero Limited | 0% | — | Unchanged |
| 4 | ANNAW | Aleanna Inc - Cl A - 29 | — | — | Unchanged |
| 5 | ANNA | Aleanna Inc | 0% | — | Unchanged |
| 6 | IWM | Ishares Russell 2000 ETF | -0.1% | +176.41% | Add |
| 7 | QXO | Qxo Inc | -0.8% | +5.40% | Trim |
| 8 | RXO | Rxo Inc | — | NEW | New buy |
| 9 | LBRDK | Liberty Broadband-c | — | EXIT | Sold out |
| 10 | SWTXUSD | Springworks Therapeutics Inc | — | EXIT | Sold out |
| 11 | LLYVK* | Liberty Media Corp-liberty-c | — | EXIT | Sold out |
| 12 | ASND | Ascendis Pharma A/S | — | EXIT | Sold out |
| 13 | RVMD | Revolution Medicines Inc | — | EXIT | Sold out |
| 14 | MLTX | Moonlake Immunotherapeutics | — | EXIT | Sold out |
| 15 | LKFT | Lakefront Biotherapeutic-adr | — | EXIT | Sold out |
| 16 | CYTK | Cytokinetics Inc | — | EXIT | Sold out |
| 17 | RNAGBP | Avidity Biosciences Inc | — | EXIT | Sold out |
| 18 | SRPT | Sarepta Therapeutics Inc | — | EXIT | Sold out |
| 19 | PRTA | Prothena Corporation plc | — | EXIT | Sold out |
| 20 | XNCR | Xencor Inc | — | EXIT | Sold out |
| 21 | EYPT | Eyepoint Inc | — | EXIT | Sold out |
| 22 | RLAY | Relay Therapeutics Inc | — | EXIT | Sold out |
| 23 | ARVN | Arvinas Inc | — | EXIT | Sold out |
| 24 | ✓ | Marblegate Acquisition CORP | — | EXIT | Sold out |
| 25 | ✓ | Summit Healthcare Acquisition | — | EXIT | Sold out |
| 26 | ✓ | Calidi Biotherapeutics Inc | — | EXIT | Sold out |
| 27 | CLDI | Calidi Biotherapeutics Inc | — | NEW | New buy |
According to official SEC Form 13F filings, Finepoint Capital LP reported a total U.S. public equity portfolio value of $2.8B across 9 disclosed positions in Q3 2025.
During Q3 2025, Finepoint Capital LP's top holdings by market value included SPY (46.3%)、QXO (24.4%)、IWM (22.5%). The largest single position, SPY, represented 46.3% of total portfolio value.
In Q3 2025, Finepoint Capital LP made 23 total portfolio adjustments, initiating 2 new buys, adding to 2 positions, trimming 1 holdings, and fully liquidating 18 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.